i
Updated Guidance for Using Intravenous Artesunate to Treat Severe Malaria in the United States
-
December 10, 2019
Details:
-
Personal Author:
-
Corporate Authors:Center for Global Health (U.S.). Division of Parasitic Diseases and Malaria. Malaria Branch. ; National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Global Migration and Quarantine. Quarantine and Border Health Services Branch. ; Center for Preparedness and Response (U.S.)
-
Description:Tuesday, December 10, 2019
In the United States, about 2,000 cases of malaria are imported each year, 300 of which are severe. There is no FDA-approved drug available to treat severe malaria. Intravenous (IV) artesunate, which is neither FDA-approved nor commercially available, is currently the first-line drug to treat severe malaria in the United States. Since April 1, 2019, all U.S. clinicians must call the CDC to obtain IV artesunate to treat cases of severe malaria.
During this COCA Call, clinicians will learn about CDC’s updated guidance for using IV artesunate—a life-saving drug—to treat patients with severe malaria in the United States, and will receive an update on CDC’s artesunate program
Combined_Malaria_COCA_Call_Presentation_December_10_2019.pdf
-
Content Notes:I.V. Artesunate as First-line for Severe Malaria in the United States / Kathrine R. Tan -- From Van to Vein : Artesunate Distribution from CDC Quarantine Stations, April 1 – October 31, 2019 / Clive M Brown.
-
Subjects:
-
Document Type:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
File Type: